Multi-specific antibodies

Delve into the world of Multi-specific antibodies in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and insights on Multi-specific antibodies to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Suzhou Rigerna Therapeutics' RG002C0106 Injection Supplemental Application Accepted by China's CDE – Class 1 Chemical Drug Enters Regulatory Review
CompanyDrug

Suzhou Rigerna Therapeutics’ RG002C0106 Injection Supplemental Application Accepted by China’s CDE – Class 1 Chemical Drug Enters Regulatory Review

Data from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) show that a supplemental application for RG002C0106 Injection, submitted by Suzhou Rigerna Therapeutics Co., Ltd.…

Hyperway Pharmaceutical Closes Series B+ Financing Round – Penglai Private Fund and Hengdian Capital Back the Chengdu Biotech's CNS and Brain‑Penetrant Drug Pipeline

Hyperway Pharmaceutical Closes Series B+ Financing Round – Penglai Private Fund and Hengdian Capital Back the Chengdu Biotech’s CNS and Brain‑Penetrant Drug Pipeline

Foresee Pharmaceuticals Announces China NMPA Approval of CAMCEVI® 42 mg for Advanced Prostate Cancer – GenSci to Commercialize the 6‑Month Leuprolide Depot

Foresee Pharmaceuticals Announces China NMPA Approval of CAMCEVI® 42 mg for Advanced Prostate Cancer – GenSci to Commercialize the 6‑Month Leuprolide Depot

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Edding Genor's GB268 Wins NMPA IND Approval for Phase II Trial – PD‑1/CTLA‑4/VEGF Trispecific Antibody Plus Chemotherapy Targets First‑Line Advanced Colorectal Cancer
CompanyDrug

Edding Genor’s GB268 Wins NMPA IND Approval for Phase II Trial – PD‑1/CTLA‑4/VEGF Trispecific Antibody Plus Chemotherapy Targets First‑Line Advanced Colorectal Cancer

Leads Biolabs' LBL‑024 Granted Second FDA Fast Track Designation – Bispecific PD‑L1/4‑1BB Antibody Advances in First‑Line Advanced Biliary Tract Cancer
CompanyDrug

Leads Biolabs’ LBL‑024 Granted Second FDA Fast Track Designation – Bispecific PD‑L1/4‑1BB Antibody Advances in First‑Line Advanced Biliary Tract Cancer

Sanofi and Regeneron Expand Alliance with $8B Next‑Generation Antibody Collaboration – Four Long‑Acting Type 2 Inflammation Programs Added Alongside Dupixent
CompanyDeals

Sanofi and Regeneron Expand Alliance with $8B Next‑Generation Antibody Collaboration – Four Long‑Acting Type 2 Inflammation Programs Added Alongside Dupixent

Leads Biolabs' LBL-024 Granted Orphan Drug Designation by Japan's MHLW – Anti‑PD‑L1/4‑1BB Bispecific Antibody Advances in Extrapulmonary Neuroendocrine Carcinoma
CompanyDrug

Leads Biolabs’ LBL-024 Granted Orphan Drug Designation by Japan’s MHLW – Anti‑PD‑L1/4‑1BB Bispecific Antibody Advances in Extrapulmonary Neuroendocrine Carcinoma

Earendil Labs Strikes Bispecific Antibody Deal with Genentech – $55 Million Upfront, Total Value Tops $1.5 Billion in Oncology
CompanyDeals

Earendil Labs Strikes Bispecific Antibody Deal with Genentech – $55 Million Upfront, Total Value Tops $1.5 Billion in Oncology

CompanyDeals

ImmuneOnco Doses First Patient in Phase 2 Trial of IMM2510 Combo for First-Line HCC

CompanyDrug

Keymed Biosciences’ Bispecific Antibody CM512 Achieves All Endpoints in Phase 2 Trial for Chronic Rhinosinusitis With Nasal Polyps

CompanyDrug

Alphamab Oncology’s Anbenitamab NDA Accepted by China NMPA for HER2+ Breast Cancer Neoadjuvant Treatment, Granted Priority Review

Show More